Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.

Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD.

Clin Infect Dis. 2003 Dec 15;37(12):1693-8. Epub 2003 Nov 17.

PMID:
14689353
2.

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Quiñones-Mateu ME, Tadele M, Parera M, Mas A, Weber J, Rangel HR, Chakraborty B, Clotet B, Domingo E, Menéndez-Arias L, Martínez MA.

J Virol. 2002 Oct;76(20):10546-52.

3.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
4.

HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.

Izopet J, Marchou B, Charreau I, Sauné K, Tangre P, Molina JM, Aboulker JP; Window (ANRS 106) Study Team..

Antivir Ther. 2008;13(4):537-45.

PMID:
18672532
5.

Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M.

J Infect Dis. 2007 Feb 1;195(3):399-409. Epub 2006 Dec 29.

PMID:
17205479
6.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.

Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.

7.

Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.

Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F.

Antivir Ther. 2007;12(3):335-43.

PMID:
17591023
8.

An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs.

van Maarseveen NM, de Jong D, Boucher CA, Nijhuis M.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):162-8.

PMID:
16645546
9.

HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

Prado JG, Parkin NT, Clotet B, Ruiz L, Martinez-Picado J.

Clin Infect Dis. 2005 Sep 1;41(5):729-37. Epub 2005 Jul 22.

PMID:
16080097
10.

Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.

Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V.

Antivir Ther. 2004 Jun;9(3):415-21.

PMID:
15259904
11.

Novel drug resistance mutations in HIV: recognition and clinical relevance.

Perno CF, Svicher V, Ceccherini-Silberstein F.

AIDS Rev. 2006 Oct-Dec;8(4):179-90. Review.

PMID:
17219733
12.

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR.

Clin Infect Dis. 2005 Jul 15;41(2):236-42. Epub 2005 Jun 7.

PMID:
15983922
14.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

15.

Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.

de Mendoza C, Rodriguez C, Corral A, del Romero J, Gallego O, Soriano V.

Clin Infect Dis. 2004 Oct 15;39(8):1231-8. Epub 2004 Sep 27.

PMID:
15486849
17.

Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.

Medeiros MS, Arruda EA, Guerrant RL, Brown CC, Lima AA.

Braz J Infect Dis. 2007 Oct;11(5):451-5.

18.

Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.

Montroni M, Monforte AD.

Scand J Infect Dis Suppl. 2003;106:79-81. Review.

PMID:
15000591
19.

The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.

Paintsil E, Margolis A, Collins JA, Alexander L.

J Med Virol. 2006 Apr;78(4):425-30.

PMID:
16482556
20.

HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.

Martinez-Picado J, Martínez MA.

Virus Res. 2008 Jun;134(1-2):104-23. doi: 10.1016/j.virusres.2007.12.021. Epub 2008 Mar 4. Review.

PMID:
18289713

Supplemental Content

Support Center